A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

被引:94
|
作者
Lu Gaohua [2 ]
Abduljalil, Khaled [2 ]
Jamei, Masoud [2 ]
Johnson, Trevor N. [2 ]
Rostami-Hodjegan, Amin [1 ,2 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England
[2] Simcyp Ltd, Sheffield, S Yorkshire, England
关键词
caffeine; metoprolol; midazolam; physiologically based pharmacokinetic model; pregnancy; BLOOD-BRAIN-BARRIER; TISSUE DISTRIBUTION; COMPUTER-MODEL; CAFFEINE; WOMEN; TRANSPORTERS; METOPROLOL; POSTPARTUM; SIMULATION; MIDAZOLAM;
D O I
10.1111/j.1365-2125.2012.04363.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Pregnant women are usually not part of the traditional drug development programme. Pregnancy is associated with major biological and physiological changes that alter the pharmacokinetics (PK) of drugs. Prediction of the changes to drug exposure in this group of patients may help to prevent under- or overtreatment. We have used a pregnancy physiologically based pharmacokinetic (p-PBPK) model to assess the likely impact of pregnancy on three model compounds, namely caffeine, metoprolol and midazolam, based on the knowledge of their disposition in nonpregnant women and information from in vitro studies. Methods A perfusion-limited form of a 13-compartment full-PBPK model (Simcyp (R) Simulator) was used for the nonpregnant women, and this was extended to the pregnant state by applying known changes to all model components (including the gestational related activity of specific cytochrome P450 enzymes) and through the addition of an extra compartment to represent the fetoplacental unit. The uterus and the mammary glands were grouped into the muscle compartment. The model was implemented in Matlab Simulink and validated using clinical observations. Results The p-PBPK model predicted the PK changes of three model compounds (namely caffeine, metoprolol and midazolam) for CYP1A2, CYP2D6 and CYP3A4 during pregnancy within twofold of observed values. The changes during the third trimester were predicted to be a 100% increase, a 30% decrease and a 35% decrease in the exposure of caffeine, metoprolol and midazolam, respectively, compared with the nonpregnant women. Conclusions In the absence of clinical data, the in silico prediction of PK behaviour during pregnancy can provide a valuable aid to dose adjustment in pregnant women. The performance of the model for drugs metabolized by a single enzyme to different degrees (high and low extraction) and for drugs that are eliminated by several different routes warrants further study.
引用
收藏
页码:873 / 885
页数:13
相关论文
共 50 条
  • [1] A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women
    Ke, Alice Ban
    Nallani, Srikanth C.
    Zhao, Ping
    Rostami-Hodjegan, Amin
    Isoherranen, Nina
    Unadkat, Jashvant D.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (04) : 801 - 813
  • [2] Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy
    Abduljalil, Khaled
    Pansari, Amita
    Jamei, Masoud
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2020, 47 (04) : 361 - 383
  • [3] Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy
    Khaled Abduljalil
    Amita Pansari
    Masoud Jamei
    Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47 : 361 - 383
  • [4] In vitro Inhibition of Human CYP1A2, CYP2D6, and CYP3A4 by Six Herbs Commonly Used in Pregnancy
    Langhammer, Astrid Jordet
    Nilsen, Odd Georg
    PHYTOTHERAPY RESEARCH, 2014, 28 (04) : 603 - 610
  • [5] Hydroxychloroquine is metabolized by CYP2D6, CYP3A4 and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A4 in vitro
    Paludetto, M.
    Kurkela, M.
    Kahma, H.
    Backman, J.
    Niemi, M.
    Filppula, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S78 - S78
  • [6] In vitro and in silico inhibition performance of choline against CYP1A2, CYP2D6 and CYP3A4
    Mateev, Emilio
    Balkanska-Mitkova, Tony
    Peikova, Lily
    Dimitrova, Maria
    Kondeva-Burdina, Magdalena
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2022, 36 (01) : 925 - 932
  • [7] The In Vitro Inhibition of Human CYP1A2, CYP2D6 and CYP3A4 by Tetrahydropalmatine, Neferine and Berberine
    Zhao, Yong
    Hellum, Bent Havard
    Liang, Aihua
    Nilsen, Odd Georg
    PHYTOTHERAPY RESEARCH, 2012, 26 (02) : 277 - 283
  • [8] PHYSIOLOGICALLY BASED PHARMACOKINETICS (PBPK) MODEL TO ASSESS CYP1A2 AND CYP3A4 INDUCTION EFFECT OF AZD7325.
    Zhou, W.
    Bui, K.
    Xu, H.
    Li, J.
    Al-Huniti, N.
    Zhou, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S55 - S55
  • [9] In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol
    L. Pan
    F. M. Belpaire
    European Journal of Clinical Pharmacology, 1999, 55 : 599 - 604
  • [10] In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol
    Pan, L
    Belpaire, FM
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (08) : 599 - 604